LASIK-Flap

Uncovering secrets of the laser eye surgery industry

The LASIK Report

A Call for the Discontinuation of a Harmful Procedure
It is currently Fri Jul 30, 2010 3:25 pm

All times are UTC - 6 hours




Post new topic Reply to topic  [ 20 posts ]  Go to page 1, 2  Next
Author Message
 Post subject: Phakic IOLs (implantable contact lenses)
PostPosted: Wed May 17, 2006 6:06 am 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
OCULAR SURGERY NEWS EUROPE/ASIA-PACIFIC EDITION
May 2006

Retinal detachment rates for lens exchange, phakic IOLs comparable

ALICANTE, Spain — Refractive lens exchange and phakic IOL implantation have similar outcomes in terms of the rate of retinal detachments, according to a speaker here.


Emanuel S. Rosen

Excerpt:


As shown by Ocular Surgery News Europe/Asia-Pacific Edition editorial board member Emanuel S. Rosen, FCOphth, at the Alicante International Refractive meeting, the annual retinal detachment rate in the general population is 0.012% and is 10 times higher after phaco extraction. In myopic eyes, the rate of retinal detachment is higher and increases to 2% to 8% after phaco extraction.

Phakic IOLs have a risk of retinal detachment similar to that of refractive lens exchange in highly myopic eyes, Mr. Rosen noted.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Fri Oct 26, 2007 10:35 am 
Offline
 Profile

Joined: Thu Nov 24, 2005 3:06 pm
Posts: 306
http://www.escrs.org/PUBLICATIONS/EUROT ... lWatch.pdf

Phakic IOLs are being used increasingly in Europe and in the US, particularly for correction of higher refractive errors. However, neither the anterior chamber nor posterior chamber IOLs are without potential postoperative problems. Complications of the former include endothelial cell loss, pupil ovalisation, induced astigmatism, glaucoma, and chronic subclinical inflammation. Problems documented with the latter include cataract formation, papillary block, pigment dispersion, and glaucoma.The situation became more serious with the recent demand by French health authorities for the withdrawal of angle-supported phakic IOLs, citing concerns about excessive endothelial cell loss. A number of articles in the August edition of the JCRS help to shed some light on issues surrounding these lenses.

_________________
Bill

"What concerns me is that if the person informing the patient is themselves poorly or inaccurately informed then how on earth can consent ever be truly informed?" Dr. Sarah Smith


Top
 
 Post subject:
PostPosted: Mon May 19, 2008 1:24 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
5/14/2008
In European experience, phakic IOLs a story of hope and disappointment

Quote:
With 20 years experience implanting phakic IOLs in Europe, phakic IOLs have "a long history of short-term success and long-term failure," French Society of Ophthalmology president Joseph Colin, MD, said here. And while early results with a new phakic IOL are encouraging, a great amount of caution is necessary.

During a joint symposium with the French Society of Ophthalmology and the American Academy of Ophthalmology, Dr. Colin reviewed the up-and-down history of the European experience with phakic IOLs and the recent problems with endothelial cell loss encountered with angle-supported phakic lenses.


Full article at:
http://www.osnsupersite.com/view.asp?rid=28260

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 6:27 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
FDA phakic intraocular lenses website
http://www.fda.gov/cdrh/phakic/

Visian
http://www.fda.gov/cdrh/pdf3/P030016.html

Visian ICL™ - P030016
http://www.fda.gov/cdrh/mda/docs/p030016.html

ARTISAN/Verisyse
http://www.fda.gov/cdrh/pdf3/P030028.html

Verisyse™ Phakic IOL - P030028
http://www.fda.gov/cdrh/mda/docs/p030028.html

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 6:41 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://www.accessdata.fda.gov/scripts/c ... _ID=853673

Hello, this letter is in regards to the staar visian icl -pma #p030016-. I had a visian lens implanted in my left eye in 2007. That evening, i noticed some strange halo/ starbursts surrounding light sources -e. G. Car headlights-. The visual artifacts look like two thirds of a spoked wheel surrounding every light. The image i see contains many -hundreds- of fairly well defined lines radiating from the light source. The lines terminate at a fairly well defined edge, where the edge itself is a well defined bright line. Also, there is a protruding secondary image from the primary image. The result is an image that looks a lot like a snow angle, where the head is the light source. At about one week post op, i visited the doctor and he gave me an eye exam, and corrected my remaining astigmatism using that test lens device they use for figuring out one's prescription. The good news was that my vision was 20/30 after correcting for my astigmatism. The bad news was that the visual artifacts were still there. They seemed unrelated to my astigmatism. My doctor consulted with a staar field representative, and both the doctor and the staar representative concluded that the vault of the icl was too high, and the icl should be replaced with a smaller version. They suspected that the high vault of the icl was causing the visual artifacts. Fourteen days later, my doctor preformed a second procedure to replace the icl with a smaller lens. That evening, i checked my vision, and unfortunately, the visual artifacts were still there. They were just as big and bright as before. My doctor tells me that the icl has excellent placement, and the vault looks great. He preformed a wave front analysis, and my cornea looks fine. A pentacam exam didn't reveal anything unusual. He doesn't know what is wrong. I got a second opinion from another ophthalmologist, but he also concluded that the implant was properly installed. I've contacted the staar company, and have worked with them somewhat to determine the problem. I've had conversations with their head of qa as well as with dr head of r&d i believe- and the inventor of the lens, but they do not know what is wrong. A note on staar. The people at staar have been somewhat repsonsive. They are not proactive about solving my problem. I initially started sending an email to them, but got no response. After two weeks i called them. I did not receive a call within two weeks, so i called them again. I got the email address of the head of qa and sent her my information and requested help. I got a reply saying that they would get back to me in a few days. I waited a week, but did not hear back. A week and a half after that qa replied. She set up a phone conference between me and the drs. A few days later, we had the phone conference. We talked for about 30 minutes, but were unable to determine the cause of my problem. They requested the results from my cornea mapping. I sent the information to them within a day or two. I've some additional information on the exact optical diameter of my lens, but i have not received a reply in over 2 months. I've also sent a letter. My opinion of the staar company is marginal at best. There customer service doesn't seem very good, and i'm surprised they do not wish to follow up on a possible problem with a product. I was/am an excellent candidate for implantation of the staar visian lens. My eyes pre-op had the following prescription: right= -16d x 2. 25d x 108, left = -18d x -1. 75d x 065. Both my pupils dilated to about 5. 75 mm. My best corrected vision was 20/40. Like many people, my pupils are off center and are somewhat nasal. I suspect i fall into a minority or patients that have an unacceptable result with the optical diameter of the staar visian lens. That is, the labeling of the staar lens states that the optical diameter of the lens is between 4. 9 and 5. 8 mm. Since my prescription is high, i'm guessing the optical diameter of my lens is closer to the lower number -i. E. 4. 9-. My dilated pupil diameter is larger, and therefore unfocused light enters my eye under low light situations. In conclusion, i would suggest the fda expand the pt criteria suitability for implantation of the staar visian lens to wear in low light conditions where the diameter of the optical portion of the lens would be such that pts would recognize visual problems in low light. In this way, pts that have problems can be disqualified from the procedure. I would also like to recommend that the labeling of the visian lens be changed to specify the exact optical diameter of each lens. That is, the range currently given -i. E. 4. 9 to 5. 8- is not precise enough. An exact diameter would give useful information. Finally, i would greatly appreciate it if the fda could contact the staar company and suggest they continue to investigate my visual problems. I've contacted other staar patients, that suffer similarly.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 6:48 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
June, 2007

Staar Surgical gets FDA warning after inspection

http://www.reuters.com/article/governme ... 5020070627

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 6:53 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://articles.latimes.com/2005/mar/05 ... /fi-staar5

Quote:
Staar, which had sales of $50.5 million in 2003, is trying to launch the first surgically implanted contact lens to correct severe nearsightedness but has stumbled in recent years. In 2003, the Food and Drug Administration found quality-control problems at Staar’s Monrovia manufacturing plant. Last month, the FDA again warned Staar of problems.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 6:55 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://www.ophmanagement.com/article.aspx?article=85996

Quote:
The violations, discovered during an FDA inspection of STAAR's Monrovia, Calif., manufacturing facility last year, fall into two major areas:

Failure to adequately report complaints concerning problems with IOLs used in cataract surgery. Under federal Medical Device Reporting (MDR) procedures, companies are required to file written reports with the FDA of any serious injuries or malfunctions associated with a medical device. The FDA says STAAR failed to report some events.

Failure to follow established procedures for approving an outside testing laboratory. The FDA said the methods used by the laboratory to test raw materials and finished devices hadn't been validated.

"You should take prompt action to correct these deviations," the FDA letter advised. "Failure to promptly correct these deviations may result in regulatory action being initiated by the FDA without further notice."

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 6:59 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://www.osnsupersite.com/view.asp?rid=27147

Quote:
The FDA then sent a warning letter to STAAR dated June 26, informing the company of numerous trial violations discovered during an inspection conducted from Feb. 15, 2007, to March 14, 2007.

“We’re on integrity hold with the Toric ICL data,” Mr. Caldwell said. The FDA is allowing an independent audit firm to review the study data for the TICL and evaluate the seven clinical sites involved, he said.

“They’ll submit a report to the FDA, and after that report is submitted to the FDA, then we’ll hopefully meet with them, and they’ll tell us what our next steps might be,” he said.

The role of the Visian ICL
The TICL approval process is reminiscent of when STAAR was working with the FDA to get the nontoric Visian ICL approved. Between 2004 and 2005, STAAR received letters from the FDA citing violations at its plant, stalling approval of the lens.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Mon Jul 14, 2008 7:05 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://www.devicelink.com/mddi/archive/04/07/011.html

Quote:
“Objectionable” Clinical Study by Staar Surgical

A recent FDA warning letter to Staar Surgical (Monrovia, CA) details objectionable clinical study conditions found during an inspection last December. However, the agency indicated that the firm’s responses to the findings generally have been adequate.

FDA conducted the inspection under a program designed to ensure that data and information submitted to the agency are scientifically valid and accurate. Such data are contained in requests for investigational device exemptions (IDEs), premarket approval applications, and premarket notification submissions. The program also ensures that human subjects are protected from undue hazard or risk during scientific investigations.
Three major areas of concern were cited in the warning letter:

• Staar provided an investigational device to a physician and started its study before FDA approval had been obtained.
• Staar failed to ensure that continuing institutional review board (IRB) approval review was received before continuation of the study.
• Staar failed to comply with sponsor responsibilities such as obtaining signed agreements from each investigator and identifying all exclusion criteria for the device.

The warning letter contained some responses from Staar vice president of scientific affairs Helene Lamielle. She said that executive staff no longer with the company had misinterpreted FDA regulations regarding custom devices.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Sat Oct 04, 2008 7:22 am 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
April 25, 2008

FDA Patient Rep asks for changes to the FDA Phakic IOL website:

http://www.fda.gov/ohrms/dockets/ac/08/ ... 3t1-04.pdf

Quote:
MS. C OFER: Yes. I'm looking on that page what are the risks, and the sentence says, "Some designs have shown that their implantation causes endothelial cells to be lost at a faster rate than normal". But my question is, isn't it all designs show a faster rate of endothelial cell loss, and not some designs?

DR. WEISS: Dr. Eydelman.

DR. EYDELMAN: Well, there are only two phakic IOLs that are currently on the market, so we can only provide -- this is an overall overview of phakic lenses, and then there's specific data specific to those two IOLs in the labeling, and summary of safety and effectiveness, so those are two different distinctions. We provide data specific to a particular device in the labeling for that device, and this is a general overview of phakic IOLs.

MS. C OFER: Can I follow-up on that?

DR. WEISS: Actually, I'm going to -- would it not be fair, because there are only two approved in the United States, to say the two that have been approved in the United States show endothelial cell loss. And I don't know, that might be addressing your point, I would hope.

MS. C OFER: My point is that both devices show an increased rate of endothelial cell loss, so it seems like this might be misleading to say some, because we have two, and they both show an increased rate of endothelial cell loss.


FDA Phakic IOL website: http://www.fda.gov/cdrh/phakic/

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Sat Oct 04, 2008 1:39 pm 
Offline
 Profile

Joined: Tue Jun 03, 2008 4:18 pm
Posts: 61
i get the impression that the patient rep is honest and the docs are squirming to distort the objective evidence


Top
 
 Post subject:
PostPosted: Wed Apr 29, 2009 2:04 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://www.fda.gov/cdrh/PDF3/p030028d.pdf

page 7

Quote:
Corneal edema occurs when the cornea takes on more water than it can absorb, which means the cornea swells and becomes less transparent. Endothelial cells play a role in keeping the cornea healthy. The available 3-year data from the clinical study indicates a continual steady loss of endothelial cells of -1.8% per year and this rate has not been established as safe. If endothelial cell loss continues at the rate of 1.8% per year, 39% of patients are expected to lose 50% of their corneal endothelial cells within 25 years of implantation. The long-term effect on the cornea's health of a 50% loss in comeal endothelial cells is unknown. However, if too many cells are lost you may need a corneal transplant. Therefore, it is very important that your endothelial cell density is periodically monitored.


http://www.fda.gov/cdrh/pdf3/p030016d.pdf

page 13

Quote:
The long-term effects on the corneal endothelium have not been established. You should be aware of potential risk of corneal edema (swelling), possibly requiring corneal transplantation. Periodic check of your endothelium are recommended to monitor the long-term health of the cornea.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Wed Apr 29, 2009 2:26 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
Instructions for searching MedWatch reports related to phakic IOLs/implantable collamer lenses (implantable contact lenses).

Use Product Code MTA.

http://www.accessdata.fda.gov/scripts/c ... Search.cfm

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
 Post subject:
PostPosted: Wed Apr 29, 2009 2:27 pm 
Offline
 Profile

Joined: Sat Nov 26, 2005 7:23 am
Posts: 3109
http://www.accessdata.fda.gov/scripts/c ... ID=1327879

Quote:
The pt reported she had lasik surgery to treat astigmatism, and had floaters prior to the implant of the icl. A 12. 6mm micl12. 6 was implanted in 2006, in the pt's right eye (od). At the three day post-operative visit, the pt's best corrected visual acuity was 20/16. At the two month post-operative visit, the best-corrected visual acuity was 20/20. In 2007, the pt's uncorrected visual acuity dropped to 20/40, due to retinal detachment. A vitrectomy was performed by a retinal specialist and the pt recovered. Due to the retinal detachment and vitrectomy, the pt developed a cataract. The icl was explanted in late 2008, and cataract surgery was performed. An iol was implanted and the pt's current best-corrected visual acuity is 20/60. The surgeon offered to perform lasik to reduce the remaining cylinder but, the pt decided not to have another lasik procedure.

_________________
Broken Eyes

"The price good men pay for indifference to public affairs is to be ruled by evil men." Plato


Top
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 20 posts ]  Go to page 1, 2  Next

All times are UTC - 6 hours


Who is online

Users browsing this forum: No registered users and 0 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Search for:
Jump to:  
Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group  
Design By Poker Bandits